SERVICES

Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Alpha-Lipoic Acid Treatment Reduces Asymmetric Dimethylarginine in Patients with Type 2 Diabetes

In a study involving 30 patients with type 2 diabetes mellitus, intravenous administration of alpha-lipoic acid (ALA) for 3 weeks was found to reduce concentrations of asymmetric dimethylarginine (mean change: -0.05 micromol/L) – which when elevated, is associated with cardiovascular events in patients with type 2 diabetes. No such change was found when placebo was administered (0.01 micromol/L). ALA treatment did not affect levels of symmetric dimethylarginine and L-arginine. The authors conclude, "Long-term studies need to demonstrate if ALA may cause cardiovascular risk reduction."

Published on 03-12-2010
Authors: Mittermayer F, Pleiner J, et al
Source: Transl Res, 2010, 155(1): 6-9